LLY

1,105.4

+0.57%↑

JNJ

207.08

-0.2%↓

ABBV

227.32

-2.16%↓

UNH

329.95

+1.06%↑

AZN

93.77

+0.73%↑

LLY

1,105.4

+0.57%↑

JNJ

207.08

-0.2%↓

ABBV

227.32

-2.16%↓

UNH

329.95

+1.06%↑

AZN

93.77

+0.73%↑

LLY

1,105.4

+0.57%↑

JNJ

207.08

-0.2%↓

ABBV

227.32

-2.16%↓

UNH

329.95

+1.06%↑

AZN

93.77

+0.73%↑

LLY

1,105.4

+0.57%↑

JNJ

207.08

-0.2%↓

ABBV

227.32

-2.16%↓

UNH

329.95

+1.06%↑

AZN

93.77

+0.73%↑

LLY

1,105.4

+0.57%↑

JNJ

207.08

-0.2%↓

ABBV

227.32

-2.16%↓

UNH

329.95

+1.06%↑

AZN

93.77

+0.73%↑

Kodu・Aktsiate loetelu・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Avatud

SektorTervishoid

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-0.05% downside

Uudiste sentiment

By Acuity

11%

89%

11 / 374 Pingereas Healthcare

Mirati Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

25. nov 2025, 16:56 UTC

Tulu

Suurimad hinnamuutused turgudel

Alimentation Couche-Tard Shares Rise as 2Q Same-Store Sales Support Profit Growth

25. nov 2025, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

25. nov 2025, 23:47 UTC

Market Talk

Nikkei May Rise After Stock Gains on Wall Street -- Market Talk

25. nov 2025, 22:39 UTC

Market Talk

Global Equities Roundup: Market Talk

25. nov 2025, 22:39 UTC

Market Talk

Vault Accelerates Exposure to Spot Gold Prices by Six Months -- Market Talk

25. nov 2025, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

25. nov 2025, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

25. nov 2025, 21:38 UTC

Tulu

HP Inc. Has a Memory Problem. Financial Forecasts Take a Hit. -- Barrons.com

25. nov 2025, 21:31 UTC

Market Talk

F&P Healthcare's Share Price Jumps on Profit Guidance Upgrade -- Market Talk

25. nov 2025, 21:27 UTC

Tulu

These Stocks Moved the Most Today: Nvidia, AMD, Alphabet, Abercrombie, Kohl's, Novo Nordisk, Symbotic, and More -- Barrons.com

25. nov 2025, 21:20 UTC

Tulu

HP Inc. Has a Memory Problem. Financial Forecasts Take a Hit. -- Barrons.com

25. nov 2025, 21:18 UTC

Tulu

NIO Stock Drops as EV Maker Posts Narrower Loss -- Barrons.com

25. nov 2025, 21:15 UTC

Tulu

HP Inc. Has a Memory Problem. Financial Forecasts Take a Hit. -- Barrons.com

25. nov 2025, 20:16 UTC

Market Talk

U.S. Natural Gas Falls as December Contract Expires -- Market Talk

25. nov 2025, 18:42 UTC

Market Talk

USDA Backs Mexican Retail Expo to Raise Agricultural Exports -- Market Talk

25. nov 2025, 18:25 UTC

Omandamised, ülevõtmised, äriostud

S&P Global Completes $1.8 Billion Acquisition Of With Intelligence, Strengthening Its Position As A Leader In Private Markets Data & Analytics >SPGI

25. nov 2025, 17:30 UTC

Market Talk

Mexico Posts Record Foreign Direct Investment for Jan-Sep -- Market Talk

25. nov 2025, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

25. nov 2025, 17:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

25. nov 2025, 16:33 UTC

Omandamised, ülevõtmised, äriostud

Eni: Financial Details Weren't Disclosed

25. nov 2025, 16:33 UTC

Omandamised, ülevõtmised, äriostud

Eni: Block OFF-5 Covers an Area of About 17,000 Km Sq. in Water Depths

25. nov 2025, 16:32 UTC

Omandamised, ülevõtmised, äriostud

Eni: Agreement to Become Effective After Approval of Uruguayan Authorities

25. nov 2025, 16:31 UTC

Omandamised, ülevõtmised, äriostud

Eni: Acquisition Is for a 50% Share, Operatorship in Exploration Block OFF-5

25. nov 2025, 16:30 UTC

Omandamised, ülevõtmised, äriostud

Eni Acquires From YPF Shares in the Exploration Block OFF-5 Offshore Uruguay

25. nov 2025, 16:23 UTC

Tulu

This Robotics Stock Soars 40% on Earnings. Here's Why. -- Barrons.com

25. nov 2025, 16:12 UTC

Market Talk

Euro Expected to Rise to $1.25 in 2026: Deutsche Bank -- Market Talk

25. nov 2025, 16:11 UTC

Market Talk

Dollar Could Take One Final Leg Lower in Early 2026 -- Market Talk

25. nov 2025, 16:10 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

25. nov 2025, 16:10 UTC

Market Talk

Sterling Could Briefly Rise After Budget -- Market Talk

25. nov 2025, 16:10 UTC

Market Talk

Oil Extends Losses on Ukraine-Russia Peace Deal Hopes -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Mirati Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-0.05% langus

12 kuu keskmine prognoos

Keskmine 58.67 USD -0.05%

Kõrge 59 USD

Madal 58 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Mirati Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Mirati Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

11 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.